A5075323142- Acute Myeloid Leukemia Research
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Death Anxiety and Social Exclusion
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Human-Animal Interaction Studies
- Behavioral Health and Interventions
Université Paris Sciences et Lettres
2024-2025
Institut Curie
2025
The University of Sydney
2023-2024
École Normale Supérieure - PSL
2024
Children's Cancer Institute Australia
2020
Abstract The overall prognosis of acute myeloid leukemia (AML) remains dismal, largely because the inability current therapies to kill stem cells (LSCs) with intrinsic resistance. Loss stress sensor growth arrest and DNA damage-inducible 45 alpha (GADD45A) is implicated in poor clinical outcomes, but its role LSCs AML pathogenesis unknown. Here, we define GADD45A as a key downstream target G protein-coupled receptor (LGR)4 pathway discover regulatory for loss promoting leukemia-initiating...
Abstract Acute myeloid leukemia (AML) is an aggressive blood cancer with limited therapeutic options against leukemic stem cells (LSCs), resulting in poor clinical outcomes for decades. We have demonstrated the importance of aberrant activation RSPO3/β-catenin pathway a subset prognosis AML (Cancer Cell, 38:263-278, 2020) and its ability to sustain low levels reactive oxygen species (ROS), critical characteristic human LSCs. This current study has extended our recent finding, first time...